DelfaGLP-1 Atlas

Lead sponsor

Altor BioScience

6 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.

6

Trials led

0

Active

137

Total enrollment

23

Sites

Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.

Portfolio

How this sponsor's trials break down

Trials by phase

Phase 1
2
Phase 1/2
4

Trials by status

Completed
3
Terminated
2
Withdrawn
1

Trials led

A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer—Ph 1/2Completed68
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies—Ph 1Completed26
QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma—Ph 1/2Completed25
A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder CancerEF ≤50%Ph 1/2Terminated12
QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple MyelomaEF ≤50%Ph 1/2Terminated6
ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia—Ph 1Withdrawnnot disclosed